<DOC>
	<DOCNO>NCT00301301</DOCNO>
	<brief_summary>There considerable international /national interest GEM−P regimen treatment patient relapsed/refractory lymphoma . Currently , accept standard therapy patient . Since publication experience regimen ( Study CCR ethic number 1857 close recruitment July 2003 : Ng M , Waters J , Cunningham D et al , Br J Cancer 2005 ; 92:1352−7 ) , treat relapsed/refractory lymphoma patient regimen would like undertake retrospective review sub−group patient diffuse large B cell lymphoma ( DLBCL ) . Patients treat GEM−P without Rituximab prior March 2005 refractory/relapsed DLBCL include analysis . Accrual eligible patient currently follow−up perform clinic time next appointment . All patient accrue give informed consent retrospective case note review , discussion study investigator receive study information sheet . All eligible patient identify pharmacy database , consent time next clinic appointment , agreeable retrospective case note review .</brief_summary>
	<brief_title>A Retrospective Review Gemcitabine , Methylprednisolone Cisplatin ( GEM-P ) With Without Rituximab Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>) Age 18 b ) Histological diagnosis diffuse large B cell lymphoma c ) Patients receive Gemcitabinecisplatin , methylprednisolone ( GEMP ) per standard unit guideline without Rituximab relapsed/refractory DLBCL . ) Informed write consent ) Medical psychiatric condition compromise patient 's ability give inform consent b ) HIV positive AIDS relate lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>